Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Reduced risk of prostate cancer in U.S. Men with AIDS.

Shiels MS, Goedert JJ, Moore RD, Platz EA, Engels EA.

Cancer Epidemiol Biomarkers Prev. 2010 Nov;19(11):2910-5. doi: 10.1158/1055-9965.EPI-10-0741. Epub 2010 Sep 13.

2.

Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations.

Jemal A, Fedewa SA, Ma J, Siegel R, Lin CC, Brawley O, Ward EM.

JAMA. 2015 Nov 17;314(19):2054-61. doi: 10.1001/jama.2015.14905.

PMID:
26575061
3.

Use of the prostate-specific antigen test among U.S. men: findings from the 2005 National Health Interview Survey.

Ross LE, Berkowitz Z, Ekwueme DU.

Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):636-44. doi: 10.1158/1055-9965.EPI-07-2709.

4.

Obesity and prostate cancer screening among African-American and Caucasian men.

Fowke JH, Signorello LB, Underwood W 3rd, Ukoli FA, Blot WJ.

Prostate. 2006 Sep 15;66(13):1371-80.

PMID:
16752375
5.

Prostate carcinoma among men with human immunodeficiency virus infection.

Crum NF, Spencer CR, Amling CL.

Cancer. 2004 Jul 15;101(2):294-9.

6.
7.

Prostate-specific antigen (PSA) screening and follow-up investigations in Māori and non-Māori men in New Zealand.

Obertová Z, Scott N, Brown C, Hodgson F, Stewart A, Holmes M, Lawrenson R.

BMC Fam Pract. 2014 Aug 26;15:145. doi: 10.1186/1471-2296-15-145.

8.

Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach.

Etzioni R, Gulati R, Falcon S, Penson DF.

Med Decis Making. 2008 May-Jun;28(3):323-31. doi: 10.1177/0272989X07312719. Epub 2008 Mar 4.

PMID:
18319508
9.

Reducing prostate cancer racial disparity: evidence for aggressive early prostate cancer PSA testing of African American men.

Powell IJ, Vigneau FD, Bock CH, Ruterbusch J, Heilbrun LK.

Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1505-11. doi: 10.1158/1055-9965.EPI-13-1328. Epub 2014 May 6.

10.

Prostate cancer incidence and prostate-specific antigen testing among HIV-positive and HIV-negative men.

Marcus JL, Chao CR, Leyden WA, Xu L, Klein DB, Horberg MA, Towner WJ, Quesenberry CP Jr, Abrams DI, Van Den Eeden SK, Silverberg MJ.

J Acquir Immune Defic Syndr. 2014 Aug 15;66(5):495-502. doi: 10.1097/QAI.0000000000000202.

PMID:
24820107
11.

Cancer incidence in the multicenter AIDS Cohort Study before and during the HAART era: 1984 to 2007.

Seaberg EC, Wiley D, Martínez-Maza O, Chmiel JS, Kingsley L, Tang Y, Margolick JB, Jacobson LP; Multicenter AIDS Cohort Study (MACS).

Cancer. 2010 Dec 1;116(23):5507-16. doi: 10.1002/cncr.25530. Epub 2010 Jul 29.

12.

Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.

Welch HG, Albertsen PC.

J Natl Cancer Inst. 2009 Oct 7;101(19):1325-9. doi: 10.1093/jnci/djp278. Epub 2009 Aug 31.

13.

Population screening for prostate cancer and emerging concepts for young men.

Moul JW.

Clin Prostate Cancer. 2003 Sep;2(2):87-97. Review.

PMID:
15040869
14.

Prostate cancer incidence and survival in relation to education (United States).

Steenland K, Rodriguez C, Mondul A, Calle EE, Thun M.

Cancer Causes Control. 2004 Nov;15(9):939-45.

PMID:
15577296
15.

Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.

Faria EF, Carvalhal GF, dos Reis RB, Tobias-Machado M, Vieira RA, Reis LO, Nogueira L, Machado RD, Freitas CH Jr, Magnabosco WJ, Mauad EC, Carvalho AL.

BJU Int. 2012 Dec;110(11 Pt B):E653-7. doi: 10.1111/j.1464-410X.2012.11398.x. Epub 2012 Aug 14.

16.

Prostate-specific antigen testing of older men.

Carter HB, Landis PK, Metter EJ, Fleisher LA, Pearson JD.

J Natl Cancer Inst. 1999 Oct 20;91(20):1733-7.

17.

Cancer burden in the HIV-infected population in the United States.

Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, Bhatia K, Uldrick TS, Yarchoan R, Goedert JJ, Engels EA.

J Natl Cancer Inst. 2011 May 4;103(9):753-62. doi: 10.1093/jnci/djr076. Epub 2011 Apr 11.

18.

Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.

Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ.

J Natl Cancer Inst. 2002 Jul 3;94(13):981-90.

19.

Prostate-specific antigen levels in the United States: implications of various definitions for abnormal.

Welch HG, Schwartz LM, Woloshin S.

J Natl Cancer Inst. 2005 Aug 3;97(15):1132-7.

20.

The impact of PSA screening on prostate cancer mortality and overdiagnosis of prostate cancer in the United States.

Howrey BT, Kuo YF, Lin YL, Goodwin JS.

J Gerontol A Biol Sci Med Sci. 2013 Jan;68(1):56-61. doi: 10.1093/gerona/gls135. Epub 2012 May 4.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk